The 2011 recommended childhood and adolescent immunization schedules have been approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, and the American Academy of Family Physicians (schedules have been provided following this article and online as Supplemental Information). These schedules are revised annually to reflect current recommendations for use of vaccines licensed by the US Food and Drug Administration and include the following changes from last year:

- Guidance for administration of the hepatitis B vaccine series for children who did not receive the recommended birth dose. A minimum age for dose 3 of hepatitis B vaccine has been added to the catch-up schedule, noting that the final (third or fourth) dose in the hepatitis B series should be administered no earlier than 24 weeks of age.

- Information on the use of the 13-valent pneumococcal conjugate vaccine (PCV13). A PCV series begun with 7-valent PCV (PCV7) should be completed with PCV13. A single supplemental dose of PCV13 is recommended for all children 14 through 59 months of age who have received an age-appropriate series of PCV7. A single supplemental dose of PCV13 is recommended for all children 60 through 71 months of age with underlying medical conditions who have received an age-appropriate series of PCV7. The supplemental dose of PCV13 should be administered at least 8 weeks after the previous dose of PCV7. A single dose of PCV13 may be administered to children 6 through 18 years of age who have functional or anatomic asplenia, HIV infection or other immunocompromising conditions, cochlear implant, or cerebrospinal fluid leak. The pneumococcal polysaccharide vaccine (PPSV) should be administered to children 2 years of age or older with certain underlying medical conditions at least 8 weeks after the last dose of PCV. A single revaccination with the PPSV should be administered after 5 years to children with functional or anatomic asplenia or an immunocompromising condition.

- Guidance for administration of 1 or 2 doses of influenza vaccine on the basis of the child’s history of receipt of monovalent 2009 H1N1 vaccine. Administer 2 doses (separated by at least 4 weeks) to children 6 months through 8 years of age who are receiving influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received 1 dose. Children 6 months through 8 years of age who received no doses of monovalent 2009 H1N1 vaccine or in whom the dosing schedule is
unknown should receive 2 doses of 2010–2011 seasonal influenza vacc-

• Guidance regarding a booster dose of quadrivalent meningococcal con-
jugate vaccine (MCV4). Adolescents should be routinely immunized, preferably at 11 through 12 years, with a booster dose at 16 years of age. Adolescents who receive their first dose at 13 through 15 years of age should receive a booster at 16 through 18 years of age. For people 2 through 54 years of age who are at increased risk of meningococcal disease, a 2-dose primary series should be administered 2 months apart. For information regarding immunization of older adolescents and adults, see the adult immunization schedule at www.cdc.gov/vaccines/recs/provisional/default.htm.

• Children 7 through 10 years of age who are not fully immunized against pertussis (including those never vaccinated or with unknown pertussis vaccine status) should receive a single dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). If further doses are needed to fully immunize against tetanus and diphtheria, children 7 through 10 years of age should be vaccinated according to the catch-up schedule. Adolescents 13 through 18 years of age who have not received the Tdap vaccine should receive a dose followed by a tetanus and diphtheria toxoids vaccine (Td) booster dose every 10 years thereafter. The reference regarding a specified time interval between the Td and Tdap vaccines has been removed from the schedule for children 7 through 18 years of age.

• Guidance for use of Haemophilus influenzae type b vaccine in people 5 years of age and older at increased risk. One dose of Haemophilus influenzae type b vaccine should be considered for people 5 years of age or older who have sickle cell disease, leukemia, or HIV infection or who have had a splenectomy.

• Guidance for the use of human papillomavirus vaccine (HPV). The quadrivalent vaccine (HPV4) and the bivalent vaccine (HPV2) are recommended for prevention of cervical precancers and cancers in females. HPV4 also is recommended for prevention of genital warts in females. HPV4 may be administered in a 3-dose series to males 9 through 18 years of age to reduce their likelihood of acquiring genital warts.

Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form can be obtained on the Internet at www.vaers.hhs.gov or by calling 800-822-7967. Additional information can be found in the 2009 Red Book1 and at Red Book Online (www.aapredbook.org). Statements from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that contain details of recommendations for individual vaccines, including recommendations for children with high-risk conditions, are available at www.cdc.gov/vaccines/pubs/ACIP-list.htm. Information on new vaccine releases, vaccine supplies, interim recommendations resulting from vaccine shortages, and statements on specific vaccines can be found at www.aapredbook.org/news/vaccstatus.shtml and www.cdc.gov/vaccines/pubs/ACIP-list.htm.

REFERENCE

**Recommended Immunization Schedule for Persons Aged 0 Through 6 Years—United States • 2011**

For those who fall behind or start late, see the catch-up schedule

<table>
<thead>
<tr>
<th>Vaccine ▼</th>
<th>Age ▲</th>
<th>Birth</th>
<th>1 month</th>
<th>2 months</th>
<th>4 months</th>
<th>6 months</th>
<th>12 months</th>
<th>15 months</th>
<th>18 months</th>
<th>19–23 months</th>
<th>2–3 years</th>
<th>4–6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>HepB</td>
<td>HepB</td>
<td>HepB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>RV</td>
<td>RV</td>
<td>RV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, Tetanus, Pertussis</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td>see footnote</td>
<td>DTaP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td>Hib</td>
<td>Hib</td>
<td>Hib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus</td>
<td>IPV</td>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella</td>
<td>MMR</td>
<td>MMR</td>
<td>Varicella</td>
<td>see footnote</td>
<td>Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>HepA (2 doses)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td>MCV4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This schedule includes recommendations in effect as of December 21, 2010. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. Considerations should include provider assessment, patient preference, and the potential for adverse events. Providers should consult the relevant Advisory Committee on Immunization Practices statement for detailed recommendations: http://www.cdc.gov/vaccines/pubs/acip-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS) at http://vaers.hhs.gov or by telephone, 800-822-7967.

1. **Hepatitis B vaccine (HepB).** (Minimum age: birth)
   - **At birth:** Administer monovalent HepB to all newborns before hospital discharge.
   - If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
   - If mother’s HBsAg status is unknown, administer HepB within 12 hours of birth. Determine mother’s HBsAg status as soon as possible and, if HBsAg-positive, administer HBIG (no later than age 1 week).

2. **Rotavirus vaccine (RV).** (Minimum age: 6 weeks)
   - **At the first dose:** Administer at age 6 through 14 weeks (maximum age: 14 weeks 6 days). Vaccination should not be initiated for infants aged 15 weeks or older.
   - **At the second dose:** Administer at age 6 through 12 weeks (maximum age: 12 weeks 6 days).
   - **At the maximum age:** After 12 weeks 6 days.

3. **Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).**
   - **Minimum age:** 6 weeks
   - **Schedule:** 0, 1, and 6 months
   - **Dose:** 3 doses
   - **Additional dose:** 1 dose at age 6 through 10 months

4. **Haemophilus influenzae type b conjugate vaccine (Hib).** (Minimum age: 6 weeks)
   - **If PRP-OMP (PedvaxHib or Comvax [HepB-Hib]):** Administer at ages 2 and 4, or 6 months for the primary series but can be used as the final dose in children aged 12 months through 4 years.
   - **If Hibrix:** Administer at ages 2 and 4, or 6 months for the primary series but can be used as the final dose in children aged 12 months through 4 years.

5. **Pneumococcal vaccine.** (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPSV])
   - **PCV** is recommended for all children aged younger than 5 years. Administer 1 dose of PCV to all healthy children aged 2 through 59 months who are not completely vaccinated for age.
   - **PPSV** is recommended for all children aged 6 to 18 years.
   - **MCV4** is recommended for all children aged 4 through 6 years.
   - **Additional dose:** All children aged 6 through 11 years who have received 4 doses of PCV should receive 1 dose of MCV4 at age 4 through 6 years.

6. **Inactivated poliovirus vaccine (IPV).** (Minimum age: 6 weeks)
   - Administer 3 doses at ages 2, 4, and 6 months.
   - **Minimum interval:** At least 4 weeks.

7. **Influenza vaccine (seasonal).** (Minimum age: 6 months)
   - **At the first dose:** Administer before age 6 months.
   - **At the second dose:** Administer before age 4 years.
   - **At the third dose:** Administer before age 4 years.

8. **Measles, mumps, and rubella vaccine (MMR).** (Minimum age: 12 months)
   - **For children aged 12 months through 12 years:** Administer 1 dose at age 12 months.
   - **For children aged 13 through 18 years:** Administer 1 dose at age 13 through 18 years.

9. **Varicella vaccine.** (Minimum age: 12 months)
   - **At the first dose:** Administer before age 4 years.
   - **At the second dose:** Administer before age 4 years.

10. **Hepatitis A vaccine (HepA).** (Minimum age: 12 months)
    - **At the first dose:** Administer before age 4 years.
    - **At the second dose:** Administer before age 4 years.

11. **Meningococcal conjugate vaccine, quadrivalent (MCV4).** (Minimum age: 2 years)
    - **At the first dose:** Administer before age 4 years.
    - **At the second dose:** Administer before age 4 years.
    - **At the third dose:** Administer before age 4 years.

12. **Additional doses:**
    - MCV4 at age 8 years for children aged 6 months through 18 years.
    - MCV4 at age 16 years for children aged 13 through 18 years.
### Recommended Immunization Schedule for Persons Aged 7 Through 18 Years—United States • 2011

For those who fall behind or start late, see the schedule below and the catch-up schedule.

<table>
<thead>
<tr>
<th>Vaccine ▼</th>
<th>Age ▼</th>
<th>7–10 years</th>
<th>11–12 years</th>
<th>13–18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, Diphtheria, Pertussis¹</td>
<td></td>
<td>Tdap</td>
<td>Tdap</td>
<td></td>
</tr>
<tr>
<td>Human Papillomavirus²</td>
<td>see footnote ²</td>
<td>HPV (3 doses)(females)</td>
<td>HPV series</td>
<td></td>
</tr>
<tr>
<td>Meningococcal³</td>
<td></td>
<td>MCV4</td>
<td>MCV4</td>
<td>MCV4</td>
</tr>
<tr>
<td>Influenza⁴</td>
<td></td>
<td>Influenza (Yearly)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal⁵</td>
<td></td>
<td>Pneumococcal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A⁶</td>
<td></td>
<td>HepA Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B⁷</td>
<td></td>
<td>Hep B Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus⁸</td>
<td></td>
<td>IPV Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella⁹</td>
<td></td>
<td>MMR Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella¹⁰</td>
<td></td>
<td>Varicella Series</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This schedule includes recommendations in effect as of December 21, 2010. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Considerations should include provider assessment, patient preference, and the potential for adverse events. Providers should consult the relevant Advisory Committee on Immunization Practices statement for detailed recommendations: [http://www.cdc.gov/vaccines/pubs/acip-list.htm](http://www.cdc.gov/vaccines/pubs/acip-list.htm). Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS) at [http://vaers.hhs.gov](http://vaers.hhs.gov) or by telephone, 800-822-7967.

1. **Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).**
   - (Minimum age: 10 years for Boostrix and 11 years for Adacel)
     - Persons aged 11 through 18 years who have not received Tdap should receive a dose followed by Td booster doses every 10 years thereafter.
     - Persons aged 7 through 10 years who are not fully immunized against pertussis (including those never vaccinated or with unknown pertussis vaccination status) should receive a single dose of Tdap. Refer to the catch-up schedule if additional doses of tetanus and diphtheria toxoid–containing vaccine are needed.
     - Tdap can be administered regardless of the interval since the last tetanus and diphtheria toxoid–containing vaccine.

2. **Human papillomavirus vaccine (HPV).**
   - (Minimum age: 9 years)
     - Quadrivalent HPV vaccine (HPV4) or bivalent HPV vaccine (HPV2) is recommended for the prevention of cervical precancers and cancers in females.
     - HPV4 is recommended for prevention of cervical precancers, cancers, and genital warts in females.
     - HPV4 may be administered in a 3-dose series to males aged 9 through 18 years to reduce their likelihood of genital warts.
     - Administer the second dose 1 to 2 months after the first dose and the third dose 6 months after the first dose (at least 24 weeks after the first dose).

3. **Meningococcal conjugate vaccine, quadrivalent (MCV4).**
   - (Minimum age: 2 years)
     - Administer MCV4 at age 11 through 12 years with a booster dose at age 16 years.
     - Administer 1 dose at age 13 through 18 years if not previously vaccinated.
     - Persons who received their first dose at age 13 through 15 years should receive a booster dose at age 16 through 18 years.
     - Administer 1 dose to previously unvaccinated college freshmen living in a dormitory.
     - Administer 2 doses at least 8 weeks apart to children aged 2 through 10 years with persistent complement component deficiency and anatomic or functional asplenia, and 1 dose every 5 years thereafter.
     - Persons with HIV infection who are vaccinated with MCV4 should receive 2 doses at least 8 weeks apart.
     - Administer 1 dose of MCV4 to children aged 2 through 10 years who travel to countries with highly endemic or epidemic disease and during outbreaks caused by a vaccine serogroup.
     - Administer MCV4 to children at continued risk for meningococcal disease who were previously vaccinated with MCV4 or meningococcal polysaccharide vaccine after 3 years (if first dose administered at age 2 through 6 years) or after 5 years (if first dose administered at age 7 years or older).

4. **Influenza vaccine (seasonal).**
   - For healthy nonpregnant persons aged 7 through 18 years (i.e., those who do not have underlying medical conditions that predispose them to influenza complications), either LAIV or TIV may be used.
     - Administer 2 doses (separated by at least 4 weeks) to children aged 6 months through 8 years who are receiving seasonal influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received 1 dose.
     - Children 6 months through 8 years of age who received no doses of monovalent 2009 H1N1 vaccine should receive 2 doses of 2010-2011 seasonal influenza vaccine. See MMWR 2010;59(No. RR-8):33–34.

5. **Pneumococcal vaccines.**
   - A single dose of 13-valent pneumococcal conjugate vaccine (PCV13) may be administered to children aged 6 through 18 years who have functional or anatomic asplenia, HIV infection or other immunocompromising condition, cochlear implant or CSF leak. See MMWR 2010;59(No. RR-11).
     - The dose of PCV13 should be administered at least 8 weeks after the previous dose of PCV7.
     - Administer pneumococcal polysaccharide vaccine at least 8 weeks after the last dose of PCV to children aged 2 years or older with certain underlying medical conditions, including a cochlear implant. A single revaccination should be administered after 5 years to children with functional or anatomic asplenia or an immunocompromising condition.

6. **Hepatitis A vaccine (HepA).**
   - Administer 2 doses at least 6 months apart.
     - HepA is recommended for children aged older than 23 months who live in areas where vaccination programs target older children, or who are at increased risk for infection, or for whom immunity against hepatitis A is desired.

7. **Hepatitis B vaccine (HepB).**
   - Administer the 3-dose series to those not previously vaccinated. For those with incomplete vaccination, follow the catch-up schedule.
     - A 2-dose series (separated by at least 4 months) of adult formulation Recombivax HB is licensed for children aged 11 through 15 years.

8. **Inactivated poliovirus vaccine (IPV).**
   - The final dose in the series should be administered on or after the fourth birthday and at least 6 months following the previous dose.
     - If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age.

9. **Measles, mumps, and rubella vaccine (MMR).**
   - The minimum interval between the 2 doses of MMR is 4 weeks.

10. **Varicella vaccine.**
    - For persons aged 7 through 18 years without evidence of immunity (see MMWR 2007;56[No. RR-4]), administer 2 doses if not previously vaccinated or the second dose if only 1 dose has been administered.
    - For persons aged 7 through 12 years, the recommended minimum interval between doses is 3 months. However, if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.
    - For persons aged 13 years and older, the minimum interval between doses is 4 weeks.
### Catch-up Immunization Schedule for Persons Aged 4 Months Through 18 Years Who Start Late or Who Are More Than 1 Month Behind—United States • 2011

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age.

#### Table: Catch-up Immunization Schedule

**Vaccine** | **Minimum Age for Dose 1** | **Dose 1 to Dose 2** | **Minimum Interval Between Doses** | **Dose 2 to Dose 3** | **Dose 3 to Dose 4** | **Dose 4 to Dose 5**
---|---|---|---|---|---|---
**PERSONS AGED 4 MONTHS THROUGH 6 YEARS**

- **Hepatitis B**
  - Administration: 3-dose series to those not previously vaccinated.
  - Minimum age: 3 months of age.
  - A 2-dose series (separated by at least 4 months) of adult formulation Recombivax HB is licensed for children aged 11 through 15 years.

- **Rotavirus vaccine (RV)**
  - The maximum age for the first dose is 14 weeks 6 days. Vaccination should not be initiated for infants aged 15 weeks 0 days or older.
  - The maximum age for the final dose in the series is 8 months 0 days.
  - If Rotarix was administered for the first and second doses, a third dose is not indicated.

- **Diphtheria and tetanus toxoid and acellular pertussis vaccine (DTaP)**
  - The third dose is not necessary if the fourth dose was administered at age 4 years or older.

- **Haemophilus influenzae type b conjugate vaccine (HiB)**
  - 1 dose of Hib vaccine should be considered for unvaccinated persons aged 5 years or older who have sickle cell disease, leukemia, or HIV infection, or who have had a splenectomy.
  - If the first 2 doses were PRP-OMP (PedvaxHiB or Comvax), and administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months at least 4 weeks after the second dose.
  - If the first dose was administered at age 7 months through 11 months, administer the second dose at least 4 weeks later and a final dose at age 12 through 15 months.

- **Pneumococcal vaccine**
  - Administer 1 dose of 13-valent pneumococcal conjugate vaccine (PCV13) to all healthy children aged 24 through 59 months with any incomplete PCV schedule (PCV7 or PCV13).
  - For children aged 24 through 71 months with underlying medical conditions, administer 1 dose of PCV13 if 3 doses of PCV were received previously or administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses of PCV were received previously.
  - A single dose of PCV13 is recommended for certain children with underlying medical conditions through 18 years of age. See age-specific schedules for details.
  - Administer pneumococcal polysaccharide vaccine (PPSV) to children aged 2 years or older with certain underlying medical conditions, including a cochlear implant, at least 8 weeks after the last dose of PCV. A single revaccination should be administered after 5 years to children with functional or anatomic asplenia or an immunocompromising condition. See MMWR 2010;59(No. RR-11).

- **Inactivated poliovirus vaccine** (IPV)
  - The final dose in the series should be administered on or after the fourth birthday and at least 6 months following the previous dose.
  - A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months following the previous dose.
  - In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk for imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).

#### Table: Specific Vaccine Precautions

- **Measles, mumps, and rubella vaccine (MMR)**
  - Administer the second dose routinely at age 4 through 6 years. The minimum interval between the 2 doses of MMR is 4 weeks.

- **Varicella vaccine**
  - Administer the second dose routinely at age 4 through 6 years.
  - If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.

- **Hepatitis A vaccine (HepA)**
  - HepA is recommended for children aged older than age 23 months who live in areas where vaccination programs target older children, or who are at increased risk for infection, or for whom immunity against hepatitis A is desired.

- **Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap)**
  - Doses of Tdap are counted as part of the Td/Tdap series.
  - Tdap should be substituted for a single dose of Td in the catch-up series for children aged 7 through 10 years as a booster for children aged 11 through 18 years; use Td for other doses.

### Additional Information

Information about reporting reactions after immunization is available online at [http://www.vaers.hhs.gov](http://www.vaers.hhs.gov) or by telephone, 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for immunization, is available from the National Center for Immunization and Respiratory Diseases at [http://www.cdc.gov](http://www.cdc.gov/vaccines) or telephone, 800-CDC-INFO (800-232-4636). Department of Health and Human Services • Centers for Disease Control and Prevention

Downloaded from [http://pediatrics.aappublications.org/](http://pediatrics.aappublications.org/) by guest on October 30, 2017
Recommended Childhood and Adolescent Immunization Schedules—United States, 2011
Committee on Infectious Diseases

*Pediatrics* 2011;127;387
DOI: 10.1542/peds.2010-3203

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://pediatrics.aappublications.org/content/127/2/387">http://pediatrics.aappublications.org/content/127/2/387</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://pediatrics.aappublications.org/content/suppl/2011/01/26/127.2.387.DC1">http://pediatrics.aappublications.org/content/suppl/2011/01/26/127.2.387.DC1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): Infectious Disease <a href="http://classic.pediatrics.aappublications.org/cgi/collection/infectious_diseases_sub">http://classic.pediatrics.aappublications.org/cgi/collection/infectious_diseases_sub</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="https://shop.aap.org/licensing-permissions/">https://shop.aap.org/licensing-permissions/</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://classic.pediatrics.aappublications.org/content/reprints">http://classic.pediatrics.aappublications.org/content/reprints</a></td>
</tr>
</tbody>
</table>
Recommended Childhood and Adolescent Immunization Schedules—United States, 2011
Committee on Infectious Diseases
Pediatrics 2011;127;387
DOI: 10.1542/peds.2010-3203

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/127/2/387